Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Intranasal Esketamine in Treatment-resistant Depression
2015-003578-34Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of esketamine in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Primary endpoint: Number of Participants With Treatment Emergent Adverse Events (TEAEs). Started Jun 2016; status: completed.
02
Drugs
esketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2015-003578-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003578-34.